BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA’s Approval for Patients with Hepatocellular Carcinoma Prior Treated with Sorafenib

 BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA’s Approval for Patients with Hepatocellular Carcinoma Prior Treated with Sorafenib

BMS’ Inrebic (fedratinib) Receives Health Canada’s Approval for Patients with Myelofibrosis

Shots:

  • The approval is based on P-I/II CheckMate -040 study assessing Opdivo (1 mg/kg, IV) + Yervoy (3 mg/kg, IV) q3w for four doses, followed by Opdivo (240mg, q2w) in 49 patients with HCC prior treated with sorafenib
  • The P-I/II CheckMate -040 study results: @28mos. follow-up, 33% of patients respond to combination therapy; CR (8%); PR (24%); DOR (4.6 to 30.5+ mos.) with 88% lasting at least 6mos., 56% at least 12mos. and 31% @24 mos.
  • Opdivo + Yervoy is the first and only dual immunotherapy approved in this setting and has received FDA’s BT & PR designation for the same indication

Click here ­to­ read full press release/ article | Ref: BMS | Image: Under Consideration

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post